D. Zhu

发表

Antihyperalgesic Effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a Novel Transient Receptor Potential Vanilloid Type 1 Modulator That Does Not Cause Hyperthermia in Rats

J. Louis, B. H. Manning, N. Gavva, 2008, Journal of Pharmacology and Experimental Therapeutics.

Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.

J. Treanor, C. Dominguez, C. Fotsch, 2006, Journal of medicinal chemistry.

AMG 9810 [(E)-3-(4-t-Butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a Novel Vanilloid Receptor 1 (TRPV1) Antagonist with Antihyperalgesic Properties

Mark H. Norman, J. Treanor, T. Vanderah, 2005, Journal of Pharmacology and Experimental Therapeutics.

The Vanilloid Receptor TRPV1 Is Tonically Activated In Vivo and Involved in Body Temperature Regulation

J. Treanor, T. Juan, J. Louis, 2007, The Journal of Neuroscience.

Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor

S. Lehto, D. Immke, K. Wild, 2016, The Journal of Pharmacology and Experimental Therapeutics.

dioxin-6-yl ) acrylamide ] , a Novel Vanilloid Receptor 1 ( TRPV 1 ) Antagonist with Antihyperalgesic Properties

J. Treanor, T. Vanderah, J. Louis, 2005 .

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.

Roman Shimanovich, Angel Guzman-Perez, R. Fremeau, 2017, Journal of medicinal chemistry.

Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel NaV1.7

Dong Liu, J. Luther, R. Fremeau, 2017, The Journal of Pharmacology and Experimental Therapeutics.

PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache?

Hantao Liu, P. Goadsby, B. Moyer, 2020, Pain.

Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade

J. Treanor, L. Arik, C. Henley, 2007, Journal of Pharmacology and Experimental Therapeutics.

Transient receptor potential melastatin 8 (TRPM8) channels are involved in body temperature regulation

N. Gavva, S. Lehto, C. Davis, 2012, Molecular pain.

TRPV1 modulator that does not cause hyperthermia in rats

J. Louis, B. H. Manning, N. Gavva, 2008 .

Antibodies to Nerve Growth Factor Reverse Established Tactile Allodynia in Rodent Models of Neuropathic Pain without Tolerance

J. Louis, A. Bannon, D. Bian, 2007, Journal of Pharmacology and Experimental Therapeutics.

TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: Compounds’ pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development

A. A. Romanovsky, A. Gomtsyan, E. Pintér, 2018, Acta physiologica.

Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel NaV1.7

J. Luther, R. Fremeau, B. Moyer, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Antihyperalgesic Effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a Novel Transient Receptor Potential Vanilloid Type 1 Modulator That Does Not Cause Hyperthermia in Rats

J. Louis, B. H. Manning, N. Gavva, 2008, Journal of Pharmacology and Experimental Therapeutics.